Dr. Pinney investigates the molecular mechanisms that link an adverse intrauterine milieu to the development of diabetes and obesity later in life. Specifically, she is researching how intrauterine growth restriction, gestational diabetes and in utero exposure to environmental toxicants contribute to the development of diabetes and obesity in offspring.
Dr. Willi's research focuses on therapeutics for type 1 and type 2 diabetes and he has performed a number of physiologic studies in the etiology and characterization of diabetes in children. His current studies include trials on the delay of progression of type 1 diabetes and a multicenter trial to examine the optimal therapeutics for type 2 diabetes in children.
Mary Ellen Vajravelu, MD, MSHP, is a pediatric endocrinologist in the Division of Endocrinology and Diabetes at Children’s Hospital of Philadelphia. She treats all pediatric endocrine conditions, but she has special expertise in prediabetes and type 2 diabetes in children and adolescents.
Dr. De Leon-Crutchlow’s translational research program focuses on examining the pathophysiology of disorders of insulin regulation, identifying novel therapeutic targets, and developing new therapies for these conditions. The program approach includes patient-oriented research and bench research employing mouse models and primary islet cultures.
Dr. Ackermann studies diabetes (types 1 and 2) and congenital hyperinsulinism using mouse models, cell lines, and primary human tissue. She aims to identify novel pathways regulating beta cell insulin secretion, leading to innovative therapeutic strategies for these disorders. Current studies include in vivo mouse physiology, ex vivo human islet physiology, CRISPR-Cas9 gene editing, epigenetic modification, and single-cell functional genomics.
Dr. Katz’s investigates the sequelae of obesity and type 2 diabetes mellitus in youth. Her research involves the intersection of sleep, obesity, and glucose intolerance and prevention of cardiovascular risk. Her studies have led to the evaluation of quantitative tools important for assessment of metabolic risk in youth.
The principal goal of Dr. Simmons' research program is to elucidate the underlying molecular mechanisms that link an aberrant intrauterine milieu to the later development of diseases in adulthood. She has made many seminal contributions to the understanding of the role that epigenetic modifications play in developmental programming of obesity and type 2 diabetes.
Dr. Roizen's research program aims to understand non-calciometabolic effects of vitamin D and to use this understanding to design new therapeutic approaches to common diseases such as sarcopenia and obesity.